Subcutaneous panniculitis-like T-cell lymphoma in a patient with history of B-cell lymphoma treated successfully with chemotherapy 15 years prior
To the Editor, Several recently published papers have suggested a possible role of traditional chemotherapy agents and/or the monoclonal antibody rituximab in the etiopathogenesis of subcutaneous panniculitis-like T-cell lymphoma (SPTCL). We read with great interest the recently published paper of Sluzevich et al., 1 documenting the appearance of a SPTCL after rituximab and cyclophosphamide therapy for chronic lymphocytic leukemia (CLL) complicated by hemolytic anemia. A French group of authors offer an important commentary in this regard as well, linking this elusive entity with the use of rituximab and cyclophosphamide. 2 We report herein a unique case of an SPTCL occurring in a patient with history of B-cell non-Hodgkin lymphoma (NHL) treated successfully 15 years prior with a regimen consisting of cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone (CHOP) without the use of rituximab.
A 71-year-old Caucasian male presented with a small painless subcutaneous nodule on the right side of occipital scalp in June 2011. He denied any other symptoms such as fever, night sweats, pruritus, or weight loss. He had history of Ann-Arbor stage IVA mixed follicular and diffuse B-cell lymphoma diagnosed 15 years previously. He was treated successfully with six cycles of CHOP chemotherapy and entered a complete remission in June 1997. He had been followed since with yearly physical examinations and intermittent radiologic staging, with no evidence of the disease relapse. Coronary artery disease was the only other comorbidity, and his medications included rosuvastatin, aspirin, fish oil, and multivitamins. Family history was significant for a low-grade B-NHL in his father who died at the age of 83, melanoma in one brother, and prostate cancer in the other. Physical examination revealed a 1-cm subcutaneous nodule in the area of right occipital scalp, a 2-cm swelling in the right preauricular area, and a palpable 1-cm lymph node in the right upper deep cervical nodal chain. There was no palpable hepatosplenomegaly. Laboratory tests revealed a normal complete blood cell count and differential. Serum chemistries and liver function tests were unremarkable. An immunoglobulin profile was within normal limits (IgA 370 mg/dL, IgG 1090 mg/ dL, and IgM 85 mg/dL), and a beta-2 microglobulin was normal (<2.0 mg/dL) as well. Biopsy of the occipital lesion revealed an inflammatory panniculitis-like cellular infiltrate with an immunohistochemistry profile revealing CD5 + CD3 + CD8 + CD30 + T-cells with aberrant loss of CD2, CD4, CD7, and CD56. Staining for PAX-5 was also negative. Three weeks later, the patient developed a suspicious nodular lesion on the left posterior neck that was excised and pathology was consistent with the same CD30 + T-cell NHL. Based on the clinical features, morphology, and immunohistochemistry patterns, a diagnosis of a SPTCL was made. A subsequent positron emission tomography (PET) study showed a moderate increase in metabolic activity in multiple areas of nearly normal-sized lymph nodes in the cervical and occipital regions. Of note, a PET scan performed 18 months prior to the appearance of the subcutaneous nodules was completely normal, and a computed tomography (CT) scan of the chest, abdomen, and pelvis six months prior did not reveal any lymphadenopathy. The patient was treated with a chemotherapy regimen consisting of gemcitabine, vinorelbine, and doxorubicin and responded well, with a good partial response.
SPTCL is a rare type of peripheral T-cell lymphoma (PTCL) affecting the skin and subcutaneous tissues and comprising less than 1% of these tumors. It is characterized by the infiltration of subcutaneous tissue by pleomorphic T-cells and macrophages. SPTCL typically presents as skin nodules that involve the extremities and trunk, but may also involve the face, neck, and back. 3, 4 SPTCL typically affects younger adults, with a median age of onset approximately two decades earlier compared with the median age at diagnosis for patients with other types of primary cutaneous T-cell NHL. 4 Therefore, our patient is rather unique in that he developed this condition in his 70 s, similarly to the patient of Sluzevich et al. 1 Clinical course of SPTCL may either be protracted over several years, with or without spontaneous regression of nodules, or rapidly progressive and fatal despite chemotherapy use. 5 The aggressive variant is commonly associated with the hemophagocytic syndrome (HPS). Of note, the SPTCL patients without HPS usually respond to either prednisone or immunosuppressive therapy, unlike other T-cell lymphomas. Our patient was no exception to this rule as he responded well to the polychemotherapy.
The pathogenesis of SPTCL is currently not well understood. Skin and subcutaneous inflammation is often referred to as cytophagic histiocytic panniculitis (CHP), which may be related to the SPTCL. Polymerase chain reaction (PCR) studies have demonstrated that CHP could be part of the same clinicopathologic spectrum as SPTCL, with SPTCL representing a neoplastic clonal process, while CHP is benign. 6 PTCL is more common in Asia, notably Japan and Caribbean islands, than in the United States and is associated with human T-lymphotropic virus type I (HTLV-1) infection. PTCL is also linked with immunosuppression, with reports in patients with human immunodeficiency virus (HIV) disease, solid organ transplantation, and chronic tumor necrosis factoralpha (TNF-alpha) inhibitor use. 7, 8 There are several proposed mechanisms involving TNF-alpha inhibitors in PTCL emergence. A possible explanation is inhibition of apoptotic pathways leading to unopposed lymphoma cell proliferation brought about by TNFalpha binding to its cell surface receptors. 9 Additionally, TNF-alpha blockade inhibits the cellmediated immunity, especially type 1 (humoral) or Th1 cytokine response that includes TNF-alpha and interferon (IFN)-gamma. This way, Th2 response is predominant in most cases of cutaneous T-cell lymphomas (CTCL) and CD30 + lymphomas, possibly leading to rapid lymphoma growth. 8 Sluzevich et al. 1 link the SPTCL in their patient with the use of rituximab and, possibly, cyclophosphamide therapy for CLL. The authors propose peripheral B-cell depletion via rituximab as the main mechanism behind the emergence of SPTCL in their patient. Indeed, depletion of normal B-cells by a single standard dose of rituximab may persist for 6-9 months. 10 However, CLL per se implies a state of immunosuppression, featuring both T-and B-cell abnormalities. 11 In addition, their case of SPTCL may represent a cyclophosphamide-related second primary neoplasm, as this agent may lead to second cancers such as bladder cancer and acute myeloid leukemia many years after exposure.
The SPTCL in our patient developed at an interval of 15 years from cyclophosphamide administration for a B-NHL. A long-term follow-up of a cohort of British patients up to 26 years after chemotherapy for NHL revealed a cumulative risk of 11.2% for a second malignancy in the first 15 years. 12 Nonetheless, T-cell lymphomas are rare in a setting of previously treated Bcell NHLs. 13 Nineteen cases of coexistent T-and B-cell lymphomas were documented by Grange et al. 14 ; however, the T-cell lymphomas in their series were CTCLs. Of these, only two patients had a documented diagnosis of B-NHL before the CTCL. Therefore, the SPTCL case of Sluzevich et al. 1 is unique in that they described it in the context of a prior CLL treated with chemotherapy and rituximab. Genetic factors may also explain the shared risk of B-and T-cell lymphomas. Notably, our patient's father also had a low-grade B-cell malignancy. Chromosomal rearrangement studies done by Vasmatzis et al. 15 identified 13 recurrent abnormalities in PTCLs, of which five were p53 genetic mutations including TP63. Rearrangements of TP63 were seen in 5.8% of PTCLs and 1.2% of diffuse large B-cell NHL. These rearrangements may represent a common abnormality linking together the B-and T-cell lymphomas.
Diagnosis and management of this very rare T-cell lymphoma type can be very challenging and requires a high index of suspicion on the side of clinician. To our knowledge, our case represents the first report of SPTCL occurring in the setting of a previously treated B-cell NHL. It is unclear whether chemotherapy, genetic factors, prior malignancy, immunosuppression, or all of the above predisposed our patient to this rare T-cell neoplasm. Hopefully, translational research models and accumulation of solid clinical experience will clarify the exact role of traditional chemotherapy and/or rituximab in the etiology of SPTCL in the coming years.
